On the road: Clinical trials with stem cell extended to non-hematologic disease


Increasing evidence in scientific journals declares that stem cell can be used in human medicine for therapeutic purposes. We reviewed the lated literature on clinical trials conducted with stem cells. The main information was offered by
http://www.ClinicalTrials.gov. These clinical trials cover almost all human diseases, from hematologic diseases to non-hematologic diseases including Interventional trials and observational trials. In conclusion, at present, the clinical trials with stem cells have been extending to almost all human diseases. Optimal medicinal effect reported in some non-hematologic diseases is pushing the advance of stem cells therapy

Share and Cite:

Yu, J. and Yu, Y. (2013) On the road: Clinical trials with stem cell extended to non-hematologic disease. Advances in Bioscience and Biotechnology, 4, 222-226. doi: 10.4236/abb.2013.42031.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Reya, T., Morrison, S.J., Clarke, M.F. and Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111. doi:10.1038/35102167
[2] Cancer statistics (Epub ahead of print) (2012).
[3] M.D. Anderson Cancer Center (2010) Decitabine and peripheral stem cell transplantation in treating patients who have relapsed following bone marrow transplantation for leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia. http://clinicaltrials.gov/ct2/show/NCT00002832
[4] St. Jude Children’s Research Hospital (2009) Haploidentical stem cell transplant for patients with sickle cell disease and prior stroke or abnormal transcranial ultrasound. http://clinicaltrials.gov/ct2/show/NCT00152113
[5] Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2012) Donor peripheral blood stem cell transplant in treating patients with hematologic malignancies. http://clinicaltrials.gov/ct2/show/NCT01028716
[6] M.D. Anderson Cancer Center (2011) Non-myeloablative allogeneic stem cell transplantation. http://clinicaltrials.gov/ct2/show/NCT00525876
[7] Efebera, Y.A., Qureshi, S.R. and Khouri, I.F. (2010) Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biology of Blood and Marrow Transplantation, 16, 1122-1129. doi:10.1016/j.bbmt.2010.02.015
[8] Fred Hutchinson Cancer Research Center (2011) Busulfan and etoposide followed by peripheral blood stem cell transplant and low-dose aldesleukin in treating patients with acute myeloid leukemia. http://clinicaltrials.gov/ct2/show/NCT00003875
[9] Emory University (2011) Combination high dose melphalan and autologous peripheral blood stem cell (PBSC) transplant with bortezomib for multiple myeloma: A dose and schedule finding study. http://clinicaltrials.gov/ct2/show/NCT00793650
[10] University of Bologna (2006) Autologous transplantation for multiple myeloma. http://clinicaltrials.gov/ct2/show/NCT00378222
[11] Fudan University (2012) IGEV followed by autologous transplantation for refractory or relapsed hodgkin lymphoma. http://clinicaltrials.gov/ct2/show/NCT01333605
[12] American Heart Association (2008) http://www.americanheart.org
[13] National Heart Institute, Mexico (2008) Intracoronary autologous stem cell transplantation in ST elevation myocardial infarction: Tracia study. http://clinicaltrials.gov/ct2/show/NCT00725738
[14] Meshalkin Research Institute of Pathology of Circulation (2012) “Estimation study” for endocardial mesenchymal stem cells implantation in patients after acute myocardial infarction. http://clinicaltrials.gov/ct2/show/NCT01394432
[15] Barts & The London NHS Trust (2011) Bone marrow derived adult stem cells for acute anterior myocardial infarction (REGEN-AMI). http://clinicaltrials.gov/ct2/show/NCT00765453
[16] University of Zurich (2008) Swiss multicenter intracoronary stem cells study in acute myocardial infarction (SWISS-AMI). http://clinicaltrials.gov/ct2/show/NCT00355186
[17] Kyoto Prefectural University of Medicine (2011) Autologous human cardiac-derived stem cell to treat ischemic cardiomyopathy (ALCADIA). http://clinicaltrials.gov/ct2/show/NCT00981006
[18] Shanghai Jiao Tong University, School of Medicine (2012) Autologous hematopoietic stem cell transplantation for early onset type 1 diabetes. http://clinicaltrials.gov/ct2/show/NCT00807651
[19] Zhang., X.F., Ye, L. and Hu, J. (2012) Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1diabetic patient. PLOS One, 7, e31887. doi:10.1371/journal.pone.0031887
[20] Boston Medical Center (2012) Bortezomib and dexamethasone followed by high-dose melphalan and stem cell transplantation for primary (AL) amyloidosis. http://clinicaltrials.gov/ct2/show/NCT01083316
[21] Stanford University (2010) Autologous stem cell rescue for primary amyloidosis. http://clinicaltrials.gov/ct2/show/NCT00186407
[22] Adistem Ltd. (2008) Safety and efficacy of autologous adipose-derived stem cell transplantation in type 2 diabetics. http://clinicaltrials.gov/ct2/show/NCT00703612
[23] Cellonis Biotechnology Co. Ltd. (2010) Stem cell therapy for type 2 diabetes mellitus. http://clinicaltrials.gov/ct2/show/NCT01142050
[24] Postgraduate Institute of Medical Education and Research (2008) Efficacy of autologous bone marrow derived stem cell transplantation in patients with type 2 diabetes mellitus (SCT). http://clinicaltrials.gov/ct2/show/NCT00644241
[25] Marmont, A.M., van Lint, M.T., Gualandi, F. and Bacigalupo, A. (1997) Autologous marrow mstem cell transplantation for systemic lupus erythematosus of long duration. Lupus, 6, 545-548. doi:10.1177/096120339700600613
[26] Fairview University Medical Center (2005) Autologous peripheral blood stem cell transplantation in patients with life threatening autoimmune diseases. http://clinicaltrials.gov/ct2/show/NCT00006055
[27] National Cancer Institute (NCI) (2012) Lymphocyte depletion and stem cell transplantation to treat severe systemic lupus erythematosus. http://clinicaltrials.gov/ct2/show/NCT00076752
[28] Charite University (2011) Autologous stem cell transplantation for refractory systemic lupus erythematosus (ASSIST). http://clinicaltrials.gov/ct2/show/NCT00750971
[29] Burt, R. (2012) Allogeneic stem cell transplantation in systemic lupus erythematosus. http://clinicaltrials.gov/ct2/show/NCT00278590
[30] National Heart, Lung, and Blood Institute (NHLBI) (2009) Allogeneic blood stem cell transplantation for patients with life-threatening systemic lupus erythematosus. http://clinicaltrials.gov/ct2/show/NCT00325741
[31] St. Jude Children’s Research Hospital (2009) Transplantation of hematopoietic cells in children with severe combined immunodeficiency syndrome. http://clinicaltrials.gov/ct2/show/NCT00152100
[32] National Human Genome Research Institute (NHGRI) (2012) Gene transfer therapy for severe combined immunodeficieny disease (SCID) due to adenosine deaminase (ADA) deficiency. http://clinicaltrials.gov/show/NCT00018018
[33] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. A Cancer Journal for Clinicians, 61, 69-90.
[34] H. Lee (2009) Combination chemotherapy followed by peripheral stem cell transplantation in treating women with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00006032
[35] Robert H. and Lurie Cancer Center (2009) Combination chemotherapy and peripheral stem cell transplantation in treating women with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00004906
[36] Northwestern University (2011) Chemotherapy, filgrastim, and stem cell transplantation with radiation therapy in treating patients with stage III or stage IV breast cancer. http://clinicaltrials.gov/show/NCT00004172
[37] www.medicinenet.com

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.